We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostic Blood Test Determines Irritable Bowel Syndrome

By LabMedica International staff writers
Posted on 21 Nov 2013
A blood test could easily determine whether a patient is suffering from Irritable Bowel Syndrome (IBS), eliminating the need for extensive and expensive dialogistic testing in order to rule out more serious conditions like Inflammatory Bowel Disease (IBD). More...


Vinculin is a cell migration and adherence protein found predominantly on nerves and epithelium and a series of studies suggests that acute gastroenteritis causes antibodies to be formed to vinculin and is associated with IBS development.

Scientists at the Cedars Sinai Medical Center (Los Angeles, CA, USA) evaluated 165 IBS, 30 IBD and 26 healthy control subjects and demographics were similar between groups. The IBS subjects were aged between 18 and 65 and were all positive according to the Rome criteria. Subjects with IBD were recruited from an expert tertiary care medical center.

Overall, IBS had a significantly greater optical density in the enzyme-linked immunoassay (ELISA) for anti-vinculin antibodies compared to IBD and healthy subjects. The results from Cedars Sinai Medical Center were compared to those at Beth Israel Deaconess Medical Center (Boston, MA, USA) for IBS recruitment, and the findings from both centers were similarly abnormal. Interestingly, subjects with a history of acute gastroenteritis, even higher levels of antibodies were seen.

Mark Pimentel, MD, the lead author of this multicenter study, said, “Anti-vinculin antibodies are elevated in IBS compared to non-IBS. This is the first diagnostic test for IBS based on serum and a pathophysiologic mechanism of IBS through acute gastroenteritis precipitating molecular mimicry and autoimmunity. This is a major breakthrough as the first test to potentially distinguish IBS from IBD and reduce the need for unnecessary testing in these conditions. Moreover, this test is based on a potential pathophysiologic mechanism of IBS development.”

In the USA, it is estimated that 10%–15% of the adult population suffers from IBS symptoms, yet only 5%–7% of adults have been diagnosed with the disease. IBS is the most common disease diagnosed by gastroenterologists and one of the most common disorders seen by primary care physicians. The study was presented at 78th Annual Scientific Meeting of the American College of Gastroenterology, held October 11-16, 2013, in San Diego (CA, USA).

Related Links:

Cedars Sinai Medical Center
Beth Israel Deaconess Medical Center 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.